ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Vertex and Moderna pursue mRNA for CF

by Michael McCoy
July 11, 2016 | APPEARED IN VOLUME 94, ISSUE 28

Vertex Pharmaceuticals and Moderna Therapeutics are joining to research Moderna’s mRNA technology for the treatment of cystic fibrosis. Vertex, which markets two CF medicines, will pay Moderna $20 million in cash and invest an equal amount in the biotech firm. Vertex could pay future milestones of up to $275 million. Moderna struck a $200 million mRNA vaccine deal with Merck & Co. late last month. It raised $450 million from investors last year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment